American Bio Medica Corp (OTC:ABMC)

American Bio Medica Corporation engages in developing, manufacturing, and marketing point of collection testing (POCT) products for drugs of abuse (DOA) in the United States and internationally. The company provides urine-based POCT products that test various drugs, including amphetamines, barbiturates, benzodiazepines, buprenorphine, cocaine, MDMA, methadone, methamphetamines, opiates, oxycodone, PCP, propoxyphene, THC, and tricyclic antidepressants. Its urine-based POCT products comprise Rapid Drug Screen to detect the presence or absence of 2 to 10 DOA; Rapid One for testing the presence or absence of a single DOA; RDS InCup, which detects the presence or absence of 2 to 12 DOA; Rapid TOX that detects the presence or absence of 2 to 10 DOA; and Rapid TOX Cup II for detecting the presence or absence of 2 to 14 DOA. The company also offers oral fluid POCT products, which test for amphetamines, barbiturates, benzodiazepines, cocaine, MDMA, methadone, methamphetamines, opiates, PCP, propoxyphene, and THC drugs. Its oral fluid POCT products include OralStat to detect DOA in oral fluids; and Rapid STAT that enhances drug recovery and provides a transport container for confirmation of positive test results. In addition, the company distributes Rapid Reader, a compact and portable unit that captures a picture of the results on an ABMC POCT product; and various POCT products to detect the presence or absence of adulterants, alcohol, and nicotine, as well as offers bulk strip contract manufacturing services to non-affiliated POCT diagnostic companies. It sells its products through direct sales and distributors. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica was founded in 1986 and is based in Kinderhook, New York.